London, UK – 06 November, 2020 – Ingenion Medical Limited, today, announces it has been awarded nearly £100,000 in grant funding from Innovate UK, the country’s innovation agency.
Ingenion will use the proceeds over the next six months to gain a CE Mark for its CymActive™ urinary catheter, a novel medical device to treat male patients suffering from chronic urinary retention.
Ingenion’s CEO Edward Cappabianca said, “Our technology’s proprietary, patent-pending magnetic valve lets patients control their urination, without surgery or drugs.”
The device, designed to work with the body’s natural defences, is expected to reduce the incidence of Catheter Associated Urinary Tract Infections (CAUTIs), significant contributors to hospital acquired infections and patient mortality.
Alistair Taylor, Chairman of Ingenion Medical, added, “This is an excellent opportunity for Ingenion to advance technology to benefit urinary retention patients. We anticipate the CymActive™ catheter will be first from our innovation pipeline to launch. We are committed to improving the health and quality of life for men and women sufferings from urinary control dysfunctions.”
About Ingenion Medical Limited: Privately held, UK-based Ingenion Medical Limited develops, manufactures, and commercializes a family of products for chronic urary retention and incontinence patients. CymActive™, its lead product, is a novel urinary catheter which can remain in-dwelling for 28 days, a dramatic quality of life improvement versus legacy solutions that often requiring multiple catheters in a single day, a common cause of infection. Visit us at: ingenionmedical.co.uk
About Innovate UK:
Innovate UK is part of UK Research and Innovation. We are the UK government’s innovation agency. Innovate UK drives productivity and economic growth by supporting businesses to develop and realise the potential of new ideas. We work with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy. Find out more about what we do.
